[{"orgOrder":0,"company":"IntelGenx","sponsor":"Cybin Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cybin Corp. and IntelGenx Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"IntelGenx"},{"orgOrder":0,"company":"Mydecine","sponsor":"Canaccord Genuity Corp.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Mydecine Innovations Group Files Preliminary Prospectus in Connection with Bought Deal Offering of Units","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mydecine"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Braxia Scientific Awarded Government of Canada Funding to Complete First of its Kind Ketamine Clinical Trial for Bipolar Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Braxia Scientific"},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mydecine"},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine Expands Portfolio Novel Molecules Filing New Patent MDMALike Compound","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mydecine"},{"orgOrder":0,"company":"Psyence","sponsor":"Pure Extracts Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"A Joint Venture Sealed between Psyence Group and Pure Extracts: Psychedelic Medicinal Mushroom Extracts in Development","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Psyence"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific Reports Encouraging Results of Ketamine Study Showing Significant Reduction in Depressive Symptoms and Suicidality with Ketamine as a Solo Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Braxia Scientific"},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mydecine"},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Mydecine"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Medicine Establishes Third R&D Partnership With the Hebrew University","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Clearmind Medicine"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Braxia Scientific Provides Update on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical Trials for Ketamine and Psilocybin Drug Development","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Braxia Scientific"},{"orgOrder":0,"company":"Psyence","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psyence Taps Another Pharma Exec to Drive its Clinical Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Psyence"},{"orgOrder":0,"company":"Optimi Health","sponsor":"SABI Mind","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Optimi Health"},{"orgOrder":0,"company":"Optimi Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Optimi Health Unveils Canada\u2019s First Natural Therapeutic Psilocybin Product For Approved Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Optimi Health"},{"orgOrder":0,"company":"Psyence","sponsor":"Brandon Kerzner","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Psyence"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"FSD Pharma"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Substance misuse is one of the most pervasive challenges around the globe, keeping this it in mind, company has announced the launch of a new research and development program focused on unmet medical needs for alcohol misuse disorder.
Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.
Research shows that up to 80 percent of patients with advanced cancer for Psilocybin are likely to suffer distressing thoughts around death and up to 50 percent of patients with generally incurable conditions are likely to have psychiatric diagnoses.
The Company has signed an agreement which will provide SABI Mind’s trained clinical staff with supplies of GMP psilocybin and 3,4-Methylenedioxymethamphetamine (“MDMA”), pending the anticipated approval of its previously announced licensing amendment.
Psyence is designing market-leading clinical trials using natural psilocybin in the field of palliative care, which will initially be conducted in the United Kingdom.
As the Company continues to focus on developing innovative treatments for depression, including potential ketamine derivatives, Braxia Scientific's team of researchers also continue to carry out multiple psychedelic-based clinical research trials.
Clearmind Medicine signed agreement to fund research and development projects with the Hebrew University of Jerusalem, Israel, focused on developing novel and patentable psychedelic molecules in search of potential drug candidates for the treatment of mental health disorders.
The application includes solutions to directly address further precision in delivery control and shelf stabilization of psilocin, psilocybin’s active metabolite, both of which are critical for use in the medical setting.
The NIDA’s decision to fund the continuation of Dr. Johnson’s smoking cessation study is a strong validator of medicines, such as MYCO001 formulation, for the treatment of smoking cessation.
Ketamine has been almost exclusively studied as an antidepressant adjunct to other antidepressants. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform.